Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

Core Viewpoint - Lexicon Pharmaceuticals has appointed Mike Exton, Ph.D. as the new CEO, succeeding Lonnel Coats, who retired on July 7, 2024. Dr. Exton brings extensive experience from Novartis, particularly in cardiometabolic therapeutics [1][2][5]. Company Leadership Changes - Mike Exton has been appointed as CEO and director of Lexicon Pharmaceuticals, with a focus on executing near-term objectives to drive future value [1][2]. - Jeff Wade has been named president and chief operating officer, having previously served as president and chief financial officer since October 2021 [2]. Leadership Experience - Dr. Exton has a 14-year tenure at Novartis, where he led the commercialization of a leading heart failure drug and developed a strong cardiometabolic business [5]. - His background includes roles in research, development, commercialization, and strategic partnerships, enhancing Lexicon's management capabilities [5]. Company Overview - Lexicon Pharmaceuticals is dedicated to pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to identify therapeutic protein targets [6]. - The company has launched INPEFA® (sotagliflozin) in the U.S. and has a pipeline of drug candidates in various stages of development for conditions such as neuropathic pain and diabetes [6].